Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer

Figures & data

Table 1. Baseline characteristics of patients with pancreatic ductal adenocarcinoma.

Factors	N (%) or median (IQR)	Missing
Age, years	68 (63–73)
Male gender	72 (51.4)
T-stage		0.7%
T1	19 (13.6)
T2	93 (66.4)
T3	26 (18.6)
T4	1 (0.7)
N-stage		1.4%
N0	32 (22.9)
N1	53 (37.9)
N2	53 (37.9)
AJCC stage, 8th edition		1.4%
IA	6 (4.3)
IB	19 (13.6)
IIA	7 (5.0)
IIB	52 (37.1)
III	54 (38.6)
Tumor differentiation		1.4%
Well	7 (5.0)
Moderate	49 (35.0)
Poor	78 (55.7)
Undifferentiated	4 (2.9)
Positive resection margin (R1)	54 (38.6)	0.7%
Adjuvant chemotherapy	113 (80.7)	3.6%

AJCC: American joint committee on cancer.

Figure 1. Representative immunohistochemical images of P4HA2 and PRTN3 expressions in pancreatic cancer.

Table 2. Cox survival analysis of P4HA2 and PRTN3 expression in pancreatic cancer.

	Disease-free survival			Overall survival
Variables	HR	95% CI	p value	HR	95% CI	p value
P4HA2, unadjusted	0.98	0.64–1.51	.929	0.74	0.49–1.13	.165
P4HA2, adjusted*	0.88	0.56–1.40	.598	0.72	0.45–1.14	.157
PRTN3, unadjusted	0.95	0.59–1.53	.837	1.14	0.70–1.85	.592
PRTN3, adjusted*	0.92	0.56–1.50	.724	1.13	0.68–1.90	.634
Low P4HA2 high PRTN3, unadjusted	4.12	1.46–11.63	.008	5.97	2.77–12.85	<.001
Low P4HA2 high PRTN3, adjusted*	3.24	1.13–9.25	.028	8.14	3.41–19.44	<.001

* Adjusted for age, gender, T-stage, N-stage, differentiation grade, resection margin status and adjuvant chemotherapy. P values in bold signify statistical significance (<.05).

Figure 2. Disease-free survival curves by P4HA2 and PRTN3 expression status in patients with pancreatic cancer.

Figure 3. Overall survival curves by P4HA2 and PRTN3 expression status in patients with pancreatic cancer.